A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain

Publication date: 1 August 2017 Source:Life Sciences, Volume 182 Author(s): J. Knoll, K. Baghy, S. Eckhardt, P. Ferdinandy, M. Garami, L.G. Harsing, P. Hauser, Z. Mervai, T. Pocza, Z. Schaff, D. Schuler, I. Miklya Aims First proof to show that (−)-deprenyl/selegiline (DEP), the first selective inhibitor of MAO-B, later identified as the first β-phenylethylamine (PEA)-derived synthetic catecholaminergic activity enhancer (CAE) substance and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP), the tryptamine-derived presently known most potent, selective, synthetic enhancer substance, are specific markers of unknown enhancer-sensitive brain regulations. Main methods Longevity study disclosing the operation of tumor-manifestation-suppressing (TMS) regulation in rat brain. Immonohist...

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2sOnyPk
via IFTTT